The complexity of the adherence-response relationship in tuberculosis treatment: Why are we still in the dark and how can we get out?

Tropical Medicine and International Health

Volumn 16, Issue 6, 2011, Pages 693-698

  Van den Boogaard, Jossy ^a,b   Boeree, Martin J ^a   Kibiki, Gibson S ^b   Aarnoutse, Rob E ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b KILIMANJARO CHRISTIAN MEDICAL CENTRE   (Tanzania)

Author keywords

Adherence rate; Treatment adherence; Treatment outcome; Tuberculosis

Indexed keywords

COMPLEXITY; DISEASE TREATMENT; DRUG RESISTANCE; EXPERIMENTAL STUDY; IMMUNOASSAY; PATHOGEN; TUBERCULOSIS;

ARTICLE; CORRELATION ANALYSIS; DRUG DOSE REGIMEN; DRUG TREATMENT FAILURE; HUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRACTICE GUIDELINE; RELAPSE; TECHNIQUE; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; BIOMEDICAL RESEARCH; HUMANS; MEDICATION ADHERENCE; TERMINOLOGY AS TOPIC; TREATMENT OUTCOME; TUBERCULOSIS;

ANIMALIA;

EID: 79955777163     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2011.02755.x     Document Type: Article

References (36)

1. American Thoracic Society (ATS), Centers for Disease Control and Prevention (CDC) & Infectious Diseases Society of America (2003) Treatment of tuberculosis. American Journal of Respiratory and Critical Care Medicine 167, 603-662.
2. Chen YC, Chang HC, Chen CJ et al. (2010) Blood absolute T cell counts may predict 2-month treatment response in patients with pulmonary tuberculosis. Disease Markers 28, 343-352.
3. Cook GM, Berney M, Gebhard S et al. (2009) Physiology of mycobacteria. Advances in Microbial Physiology 55, 81-89.
4. De Steenwinkel JE, De Knegt GJ, Ten Kate MT et al. (2009) Immunological parameters to define infection progression and therapy response in a well-defined tuberculosis model in mice. International Journal of Immunopathology and Pharmacology 22, 723-734.
5. Diacon AH, Maritz JS, Venter A et al. (2010) Time to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early bactericidal activity of antituberculosis agents. European Journal of Clinical Microbiology & Infectious Diseases 29, 1561-1565.
6. Drlica K & Zhao X (2007) Mutant selection window hypothesis updated. Clinical Infectious Diseases 44, 681-688.
7. Drusano GL, Louie A, Deziel M & Gumbo T (2006) The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulations. Clinical Infectious Diseases 42, 525-532.
8. Farmer KC (1999) Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clinical Therapeutics 21, 1074-1090.
9. Gelband H (2000) Regimens of less than six months for treating tuberculosis. Cochrane Database Systematic Review 2, CD001362.
10. Guerra RL, Conde MB, Efron A et al. (2010) Point-of-care Arkansas method for measuring adherence to treatment with isoniazid. Respiratory Medicine 104, 754-757.
11. Gumbo T, Louie A, Deziel MR et al. (2007a) Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrobial Agents and Chemotherapy 51, 3781-3788.
12. Gumbo T, Louie A, Liu W et al. (2007b) Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrobial Agents and Chemotherapy 51, 2329-2336.
13. Gumbo T, Dona CS, Meek C & Leff R (2009) Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrobial Agents and Chemotherapy 53, 3197-3204.
14. Hall RG, Leff RD & Gumbo T (2009) Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 29, 1468-1481.
15. Jayaram R, Gaonkar S, Kaur P et al. (2003) Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrobial Agents and Chemotherapy 47, 2118-2124.
16. Jayaram R, Shandil RK, Gaonkar S et al. (2004) Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrobial Agents and Chemotherapy 48, 2951-2957.
17. Johnson JL, Hadad HD, Diteze R et al. (2009) Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. American Journal of Respiratory and Critical Care Medicine 180, 558-563.
18. Ma Z, Lienhardt C, McIlleron H, Nunn AJ & Wang X (2010) Global tuberculosis drug development pipeline: the need and the reality. Lancet 375, 2100-2109.
19. Mason CM & Ali J (2004) Immunity against Mycobacteria. Seminars in Respiratory and Critical Care Medicine 25, 53-61.
20. Mitchison DA (2000) Role of individual drugs in the chemotherapy of tuberculosis. International Journal of Tuberculosis and Lung Disease 4, 796-806.
21. Moulding TS (2007) Viewpoint: adapting to new international tuberculosis treatment standards with medication monitors and DOT given selectively. Tropical Medicine and International Health 12, 1302-1308.
22. Moulding T, Ellis D & Turk R (2010) Electronic medication monitors: status of development and potential for improving effective TB treatment programs. Last accessed January 17, 2011 at.
23. Munro S, Lewin S, Swart T & Volmink J (2007) A review of health behaviour theories: how useful are these for developing interventions to promote long-term medication adherence for TB and HIV/AIDS? BMC Public Health 7, 104, doi: 10.1186/1471-2458-7-104.
24. Nuermberger E & Grosset J (2004) Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. European Journal of Clinical Microbiology & Infectious Diseases 23, 243-255.
25. Osterberg L & Blaschke T (2005) Adherence to medication. The New England Journal of Medicine 353, 487-497.
26. Paterson DL, Swindells S, Mohr J et al. (2000) Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine 133, 21-30.
27. Perrin FM, Lipman MC, McHugh TD & Gillespie SH (2007) Biomarkers of treatment response in clinical trials of novel antituberculosis agents. The Lancet Infectious Diseases 7, 481-490.
28. Ruslami R, Van Crevel R, Van de Berge E, Alisjahbana B & Aarnoutse RE (2008) A step-wise approach to find a valid and feasible method to detect non-adherence to tuberculosis drugs. The Southeast Asian Journal of Tropical Medicine and Public Health 39, 1083-1087.
29. Sharma SK & Mohan A (2006) Multidrug-resistant tuberculosis: a menace that threatens to destabilize tuberculosis control. Chest 130, 261-272.
30. Srivastava S, Musuka S, Sherman C et al. (2010a) Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. Journal of Infectious Diseases 201, 1225-1231.
31. Srivastava S, Wozniakowski A, Pasipanodya J & Gumbo T (2010b) Treatment failure and emergence of resistance during non-compliance in an experimental animal model. 3rd International Workshop on Clinical Pharmacology of Tuberculosis Drugs. Boston, MA, USA. Abstract 3 TB-P-0009.
32. Volmink J & Garner P (2007) Directly observed therapy for treating tuberculosis. Cochrane Database Systematic Review 4, CD003343.
33. Wallis RS, Vinhas SA, Johnson JL et al. (2003) Whole blood bactericidal activity during treatment of pulmonary tuberculosis. Journal of Infectious Diseases 187, 270-278.
34. WHO (2002) An Expanded DOTS Framework for Effective Tuberculosis Control. Stop TB Communicable Diseases. WHO, Geneva; WHO/CDS/TB/2002.297.
35. WHO (2003) Treatment of Tuberculosis. Guidelines for National Programmes. 3rd edn. WHO, Geneva; WHO/CDS/TB/2003.313.
36. WHO (2010) Global Tuberculosis Control 2010. WHO, Geneva; WHO/HTM/TB/2010.7.